

## Pirfenidone Clinical trials

| <b>Disease</b>                     | <b>Dose and time</b>         | <b>Type of study</b>                             | <b>Number of patients</b> | <b>Effects</b>                                                                                                                             | <b>Reference</b> |
|------------------------------------|------------------------------|--------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Interstitial pulmonary fibrosis    | 3600 mg/daily x over 2 years | Open-label study                                 | 54                        | Increase in 1 and 2 year survival. Stabilize lung function.                                                                                | 42               |
| Interstitial pulmonary fibrosis    | 600 mg t.i.d x 9 Mo          | Double-blind randomized placebo controlled trial | 107                       | Improvement in SpO2 during a 6-minute exercise test. No episodes of acute exacerbation of IPF in PDF group.                                | 43               |
| Hermansky–Pudlak syndrome          | 800 mg t.i.d. x 44 Mo        | Randomized placebo-controlled trial              | 11                        | Lost of pulmonary functions at a slower rate.                                                                                              | 44               |
| HCV related liver disease          | 1200 mg/daily x 12 Mo        | Open label pilot study                           | 15                        | 30% of patients had less fibrosis after treatment. Down-regulation of Col I, TGFβ and TIMP-1. Improvement in quality of life (SF-36 test). | 55               |
| Focal segmental glomerulosclerosis | 800 mg t.i.d x 5-37 Mo       | Open-label pilot study                           | 18                        | Slows renal function decline. Improvement of 25%                                                                                           | 67               |
| Hypertrophic scars                 | PDF in gel at 8% x 6 Mo      | Open label pilot study                           | 33                        | Improvement in the Vancouver scar score in 66.6% of patients.                                                                              | 70               |